Bayer Korea Divests OTC Oral Contraceptives To Gain Merck’s Market-Leading Brand
This article was originally published in The Tan Sheet
In the first move by a South Korean pharma to acquire global brand drugs, Dong-A Pharm takes over four oral contraceptive products from Bayer Korea to beef up its OTC business and female product portfolios. Bayer Korea, meanwhile, turns its acquisition sights on MSD Korea’s market-leading Mercilon.
You may also be interested in...
Bayer closes its acquisition of Merck & Co.’s consumer business, aiming to become the top OTC player and saying other consumer product acquisitions could follow. Glaxo and Novartis look to close their agreement to combine their OTC businesses in the first half of 2015.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Hanmi Pharm is remaining upbeat after Sanofi’s decision to find another commercialization partner for efpeglenatide, saying it was the best strategy for the long-acting GLP-1 agonist given the strategic change in the big pharma’s diabetes strategy.